Skip to main content
Premium Trial:

Request an Annual Quote

Boehringer Ingelheim to Use IDBS' Predictive Modeling

NEW YORK (GenomeWeb News) – Boehringer Ingelheim researchers will use IDBS’ predictive modeling technology in its drug discovery research programs, IDBS said today.
Pharmaceutical researchers at Boehringer Ingelheim’s Biberach an der Riss facility will use IDBS’ PredictionBase “to increase efficiency of the candidate identification process,” IDBS founder and CEO Neil Kipling said in a statement.
Guildford, UK-based IDBS said the scientists will use PredictionBase to build, deploy, and distribute predictive ADME quantitative structure-activity relationship models using existing data.
Financial terms of the agreement were not released.
In addition to its UK headquarters, IDBS has offices in California, New Jersey, and Massachusetts.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.